Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. engages in the discovery and development of medicines for the treatment of cancer and related conditions in the United States. Its lead product candidate includes IPI-504 (retaspimycin hydrochloride), an intravenously-administered small molecule inhibitor of heat shock protein 90 (Hsp90). The Company is conducting an international Phase II clinical trial of IPI-504 in combination with Herceptin in patients with HER2-positive metastatic breast cancer; a Phase II clinical trial of IPI-504 in patients with advanced non-small cell lung cancer; and a Phase I clinical trial of IPI-504 in combination with Taxotere in patients with advanced solid tumors. Its products under Phase I clinical trial comprise IPI-493, an orally-delivered inhibitor of Hsp90, in patients with advanced solid tumors; IPI-926 for patients with advanced and/or metastatic solid tumors; and IPI-940, an orally-delivered inhibitor of fatty acid amide hydrolase for the treatment of neuropathic and inflammatory pain.

Company Growth (employees)
Type
Public
HQ
Cambridge, US
Founded
2001
Size (employees)
222 (est)
Website
infi.com
Infinity Pharmaceuticals was founded in 2001 and is headquartered in Cambridge, US

Key People at Infinity Pharmaceuticals

David A. Roth

David A. Roth

Senior Vice President, Clinical Development and Medical Affairs
Joseph F. McPherson

Joseph F. McPherson

Vice President, Vendor Management/Sourcing and Facilities Operations
Lawrence E. Bloch

Lawrence E. Bloch

Executive Vice President, Chief Financial Officer and Chief Business Officer
Julian Adams

Julian Adams

President, Research and Developmen
Tamyra A. Toole

Tamyra A. Toole

Vice President, Regulatory affairs and Quality Assurance

Infinity Pharmaceuticals Office Locations

Infinity Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
780 Memorial Drive

Infinity Pharmaceuticals Data and Metrics

Infinity Pharmaceuticals Financial Metrics

Infinity Pharmaceuticals's revenue was reported to be $18.7 m in FY, 2016
USD

Net income (Q1, 2017)

(10.5 m)

EBIT (Q1, 2017)

(10.5 m)

Market capitalization (15-Aug-2017)

54.5 m

Cash (31-Mar-2017)

75.4 m
Infinity Pharmaceuticals's current market capitalization is $54.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

165 m109.1 m18.7 m

Revenue growth, %

(34%)(83%)

R&D expense

119.6 m

General and administrative expense

42.2 m

Operating expense total

127.7 m172.9 m236.2 m161.8 m

EBIT

(127.7 m)(7.9 m)(127.1 m)(30.9 m)

EBIT margin, %

(5%)(117%)(165%)

Interest expense

9.6 m1.4 m(1.2 m)

Pre tax profit

(126.8 m)(17.2 m)(128 m)(30.1 m)

Net Income

(126.8 m)(17.4 m)(128.4 m)(30.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

28.2 m44.9 m88.4 m34.1 m37.7 m39.2 m52.9 m12.8 m4 m

General and administrative expense

7.1 m8 m8.6 m9.4 m9.8 m10.8 m15.7 m7.1 m6.4 m

Operating expense total

35.2 m52.9 m97 m43.5 m47.5 m50 m68.6 m19.9 m10.5 m

EBIT

(35.2 m)107.7 m(92.6 m)(38.6 m)43.3 m(40.8 m)53 m(19.9 m)(10.5 m)

Interest expense

(2.9 m)(4.5 m)(647 k)(99 k)(311 k)(309 k)(307 k)(305 k)(302 k)

Pre tax profit

43 m(19.5 m)

Net Income

(38 m)103.2 m(93.3 m)(38.4 m)42.5 m(40.7 m)53 m(19.5 m)(10.5 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

68.1 m307.4 m188.2 m74.1 m

Inventories

11.1 m11.2 m9.5 m8.4 m

Current Assets

224.9 m344.6 m254.7 m101.7 m

PP&E

4 m19 m28.2 m23.4 m

Total Assets

230.7 m369.1 m288.8 m125.7 m

Accounts Payable

6.4 m5.9 m9.6 m2.4 m

Current Liabilities

22.2 m54.9 m70.1 m23.9 m

Total Liabilities

43.2 m

Additional Paid-in Capital

650.9 m676.5 m694.1 m708.1 m

Retained Earnings

(449.8 m)(467.2 m)(595.6 m)(625.7 m)

Total Equity

201.3 m209.5 m98.6 m82.5 m

Financial Leverage

1.1 x1.8 x2.9 x1.5 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

85.5 m321.3 m223 m134.6 m137.3 m113.8 m122.4 m98.5 m75.4 m

Current Assets

160.2 m390.7 m239.4 m208.5 m300.3 m208 m157.5 m123.5 m80.3 m

PP&E

3.4 m3 m22.7 m27.4 m28.1 m27.9 m25.7 m24.5 m22.7 m

Total Assets

165.6 m396.8 m267.6 m240.9 m333.2 m240.5 m187.3 m151.9 m103.6 m

Accounts Payable

3.9 m11 m5.7 m7.8 m11.2 m9.1 m12.7 m4.8 m733 k

Current Liabilities

26.5 m58.4 m44.3 m58.2 m74.3 m66.8 m44.3 m25.9 m10.6 m

Additional Paid-in Capital

668.4 m672.2 m681.4 m686.1 m690 m697.8 m702 m704.8 m709.9 m

Retained Earnings

(530.1 m)(426.9 m)(560.5 m)(598.9 m)(556.4 m)(636.3 m)(583.3 m)(602.8 m)(636.2 m)

Total Equity

138.5 m245.5 m121.1 m87.3 m133.6 m61.6 m118.8 m102.1 m73.8 m

Financial Leverage

1.2 x1.6 x2.2 x2.8 x2.5 x3.9 x1.6 x1.5 x1.4 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(126.8 m)(17.4 m)(128.4 m)(30.1 m)

Depreciation and Amortization

1.8 m1.8 m2.3 m3.4 m

Cash From Operating Activities

(113.9 m)117.7 m(83.7 m)(154.4 m)

Purchases of PP&E

(1.8 m)(1.4 m)(6.4 m)(661 k)

Cash From Investing Activities

606 k117.9 m(37.9 m)40.3 m

Cash From Financing Activities

5.7 m3.7 m2.3 m(83 k)

Interest Paid

721 k1.2 m

Income Taxes Paid

885 k5 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(38 m)103.2 m(93.3 m)(38.4 m)42.5 m(40.7 m)53 m(19.5 m)(10.5 m)

Accounts Payable

3.9 m11 m5.7 m7.8 m11.2 m9.1 m12.7 m4.8 m733 k
Y, 2017

Financial Leverage

1.4 x

Infinity Pharmaceuticals Market Value History

Traffic Overview of Infinity Pharmaceuticals

Infinity Pharmaceuticals Online and Social Media Presence

Infinity Pharmaceuticals Company Life and Culture

You may also be interested in